title: Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide.
authors.affiliation: Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
authors.forename: Ashley M
authors.initials: AM
authors.lastname: Hopkins
authors.affiliation: Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
authors.forename: Agnes I
authors.initials: AI
authors.lastname: Vitry
authors.affiliation: Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
authors.forename: Catherine E
authors.initials: CE
authors.lastname: O'Doherty
authors.affiliation: Department of Rheumatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.|Discipline of Medicine, Adelaide University, Adelaide, South Australia, Australia.
authors.forename: Susanna M
authors.initials: SM
authors.lastname: Proudman
authors.affiliation: Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Wiese
mesh_terms: D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics; D001315:Australia; D001688:Biological Products / Q000191:economics / Q000627:therapeutic use*; D000066491:Clinical Decision-Making; D016527:Drug Costs / Q000331:legislation & jurisprudence / Q000639:trends*; D017723:Drug Utilization Review; D005102:Health Expenditures / Q000639:trends; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use*; D000077339:Leflunomide / Q000191:economics / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians' / Q000191:economics / Q000331:legislation & jurisprudence / Q000639:trends*; D015397:Program Evaluation; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products; D007166:Immunosuppressive Agents; D000077339:Leflunomide